6:19 PM
 | 
Jul 31, 2013
 |  BC Extra  |  Top Story

FibroGen, AstraZeneca in anemia deal

FibroGen Inc. (San Francisco, Calif.) and AstraZeneca plc (LSE:AZN; NYSE:AZN) partnered to develop and commercialize FibroGen's anemia compound FG-4592 worldwide, excluding the countries in which Astellas Pharma Inc. (Tokyo:4503) already has rights. FibroGen and AstraZeneca will...

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >